Physician profile
Lewis B Eberly
NPI 1841282555
$6,609.89
in general payments reported to CMS, 2019-2025
45 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,993 · 2020: $546 · 2021: $710 · 2022: $1,161 · 2023: $1,570 · 2024: $498 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.35 | 2021-2025 | Duopa, Botox, Ubrelvy |
| Ucb, INC. | $833.46 | 2019-2023 | Fintepla |
| Sunovion Pharmaceuticals INC. | $406.95 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $265.33 | 2019-2020 | |
| Inspire Medical Systems, INC. | $222.17 | 2023-2024 | Inspire |
| Avanir Pharmaceuticals, INC. | $217.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $216.75 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $197.18 | 2019-2025 | Rytary, Lyvispah, Crexont |
| Adamas Pharmaceuticals, INC. | $188.56 | 2019-2021 | |
| Allergan, INC. | $188.22 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $187.88 | 2019-2020 | |
| Biogen, INC. | $187.42 | 2019-2022 | |
| Ge Healthcare | $186.70 | 2023-2025 | |
| Harmony Biosciences LLC | $182.39 | 2022-2025 | Wakix |
| Teva Pharmaceuticals USA, INC. | $172.64 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Eberly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.